




The relative strengths and weaknesses of Matinas Biopharma Holdings Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Matinas Biopharma Holdings Inc compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 11% points. The greatest weakness of Matinas Biopharma Holdings Inc is the variable Net Income, reducing the Economic Capital Ratio by 78% points.

The company's Economic Capital Ratio, given in the ranking table, is 133%, being 82% points below the market average of 215%.

Input Variable	Value in 1000 USD
Assets, Current	8,025
Cost of Goods Sold	0
Intangible Assets	2,260
Liabilities, Current	2,666
Liabilities, Non-Current	2,385
Other Assets	1,888
Other Compr. Net Income	221
Other Expenses	4,351
Other Liabilities	0
Other Net Income	262
Other Revenues	0
Property and Equipment	468
Research and Development	11,433
Selling, General and Administrative Expense	8,729

Output Variable	Value in 1000 USD
Assets	12,641
Liabilities	5,051
Expenses	24,513
Revenues	0
Stockholders Equity	7,590
Net Income	-24,251
Comprehensive Net Income	-24,140
BaseVar	21,344
ECR before Limited Liability	-86%
Economic Capital Ratio	133%